Delivery Order SPE2DB22D1106-SPE2DB25FEKK9
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,343.59 by the Defense Logistics Agency on August 22, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This competitively awarded, firm fixed-price contract carries an ultimate completion date of September 15, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award involves no set-aside designation, reflecting the company's competitive standing in federal...
- AmerisourceBergen Drug Corp was awarded a $4,687.18 delivery order by the Defense Logistics Agency (DLA) Medical Supply Chain on September 17, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by October 8, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors with an ultimate completion date of September 11, 2025. This competitive award was issued under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,343.59 on July 21, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by August 11, 2025, with performance taking place at the company's Conshohocken facility. The contract was funded by the Defense Logistics Agency's Medical Supply Chain division to...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectables. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $4,687.18 on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. Performance will be completed by September 3, 2025, with fulfillment conducted from the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $9,374.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors on July 16, 2025, with completion by August 6, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a $18,748.72 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with performance completion by September 30, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger federal contracting vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania....
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $2,343.59 delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of July 11, 2025. This firm fixed-price, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEKK9Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,374.36 by the Defense Logistics Agency (DLA) on April 24, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. This firm fixed-price delivery order, which carries an ultimate completion date of May 15, 2025, represents a competitive award with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. Tezspire is a biologic medication used in the treatment of moderate-to-severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical supply requirements, ranging from specialty medications and vaccines to medical devices and diagnostic supplies across multiple therapeutic areas. The SPE2DX umbrella contract enables AmerisourceBergen to serve customers including the Defense Health Agency and U.S. Coast Guard, positioning the company as a key vendor within the federal healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 4/24/25 |